NicOx partners with Bausch & Lomb for its candidate glaucoma drug

March 3, 2010

Article

A worldwide licensing deal has been made between NicOx, the French biotech business and Bausch & Lomb for the former's candidate glaucoma drug NCX 116.

A worldwide licensing deal has been made between NicOx, the French biotech business and Bausch & Lomb for the former's candidate glaucoma drug NCX 116.

B&L will also be able to consider development and marketing of other products containing NCX 116 under the terms of the agreement. Phase II trials have been completed and clinical trials in patients with glaucoma and ocular hypertension are underway.

Recent Videos

Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT

Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium

I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.

Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times

Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting

Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA

Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting

Related Content

A flip-calendar shows March 31st as the date, while the United States Food and Drug Administration and European Medicines Agency logos hover above. Image credit: ©Jenn Miranda, via Canva. FDA and EMA logos courtesy respective agencies.

Retina recap: EMA and US FDA approvals, March 2025

Regulatory agencies issued approvals for new treatments and expanded uses of existing therapies in the retina space

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD

An image of a person pressing a computer shutdown button, superimposed digitally over the image. Concept for clinical trial discontinuation. Image credit: ©natali_mis – stock.adobe.com

Opthea discontinues COAST and ShORe sozinibercept combination therapy trials

Martin David Harp

Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration

A woman with myopia holds a pair of glasses at a distance and looks through the vision-correcting lens. Paediatric myopia control concept. Image credit: ©Chanintorn.v – stock.adobe.com

French OPHTAMYOP study reveals trends in myopia control

Dominique Bremond-Gignac, MD, PhD, FEBO

How studies into myopia management can increase access to vision care

An image of the European Medicines Agency (EMA) headquarters to accompany a CHMP opinion. Image credit: ©Lubo Ivanko – stock.adobe.com

EMA grants positive CHMP opinion for low-dose atropine SYD-101 (Ryjunea, Sydnexis)

A pivotal phase 3 clinical trial found that SYD-101 met its 3-year primary endpoint for slowing paediatric myopia progression

A close-up of a doctor's face. The doctor wears PPE including a mask and safety goggles. Oncology and ophthalmology concept image. Image credit: ©H_Ko – stock.adobe.com

New study investigates ocular involvement in multiple myeloma

Hematologists and ophthalmologists could work together for earlier diagnoses, research findings indicate

Related Content

A flip-calendar shows March 31st as the date, while the United States Food and Drug Administration and European Medicines Agency logos hover above. Image credit: ©Jenn Miranda, via Canva. FDA and EMA logos courtesy respective agencies.

Retina recap: EMA and US FDA approvals, March 2025

Regulatory agencies issued approvals for new treatments and expanded uses of existing therapies in the retina space

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD

An image of a person pressing a computer shutdown button, superimposed digitally over the image. Concept for clinical trial discontinuation. Image credit: ©natali_mis – stock.adobe.com

Opthea discontinues COAST and ShORe sozinibercept combination therapy trials

Martin David Harp

Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration

A woman with myopia holds a pair of glasses at a distance and looks through the vision-correcting lens. Paediatric myopia control concept. Image credit: ©Chanintorn.v – stock.adobe.com

French OPHTAMYOP study reveals trends in myopia control

Dominique Bremond-Gignac, MD, PhD, FEBO

How studies into myopia management can increase access to vision care

An image of the European Medicines Agency (EMA) headquarters to accompany a CHMP opinion. Image credit: ©Lubo Ivanko – stock.adobe.com

EMA grants positive CHMP opinion for low-dose atropine SYD-101 (Ryjunea, Sydnexis)

A pivotal phase 3 clinical trial found that SYD-101 met its 3-year primary endpoint for slowing paediatric myopia progression

A close-up of a doctor's face. The doctor wears PPE including a mask and safety goggles. Oncology and ophthalmology concept image. Image credit: ©H_Ko – stock.adobe.com

New study investigates ocular involvement in multiple myeloma

Hematologists and ophthalmologists could work together for earlier diagnoses, research findings indicate

Editorial Board

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.